ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.045

-3.1%

1:53 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jargonweary	4/16/2025 11:11:25 AM
	of 1229

I have a slight but still nagging concern that our pending drug approval in Europe could get caught up in the irrational trade war that has been started. Reciprocal tariffs are not the only way that nations retaliate in trade wars; there are multiple ways that so-called “non-tariffs trade barriers” can be implemented that punish former trade partners by imposing technical restrictions and delayed or even denied approvals of things that formerly would have been routinely approved. Would a delay of Anktiva approval hurt European citizens? Of course it would. But as we have seen, imposing pain on a nations own citizens is often viewed by trade warriors as an acceptable price to pay in a trade war. My fear is that this might happen in response to rumored tariffs against pharma companies that manufacture drugs outside of the US.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next